Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AIDS ; 21(18): 2543-6, 2007 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-18025896

RESUMO

After 12 weeks of rosiglitazone treatment, significant increases in total and small dense low-density lipoprotein, and the total: high-density lipoprotein (HDL)-cholesterol ratio were found. The large HDL concentration and HDL particle size decreased significantly with rosiglitazone compared with placebo. These data indicate the production of a more atherogenic lipid profile with rosiglitazone, a consideration when selecting treatment for the growing population of HIV-infected patients with type 2 diabetes and dyslipidemia.


Assuntos
Síndrome de Lipodistrofia Associada ao HIV/tratamento farmacológico , Hipoglicemiantes/efeitos adversos , Lipoproteínas HDL/sangue , Lipoproteínas LDL/sangue , Tiazolidinedionas/efeitos adversos , Adulto , Feminino , Seguimentos , Síndrome de Lipodistrofia Associada ao HIV/sangue , Humanos , Hipoglicemiantes/uso terapêutico , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , PPAR gama/agonistas , Tamanho da Partícula , Rosiglitazona , Tiazolidinedionas/uso terapêutico
2.
J Clin Endocrinol Metab ; 90(6): 3423-6, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15741250

RESUMO

Resistin is a recently recognized adipocytokine thought to contribute to insulin resistance. We determined resistin levels and metabolic parameters in 24 HIV-infected men and women with lipoatrophy and hyperinsulinemia and studied the effect of 12 wk of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (4-8 mg/d) on resistin in these subjects. Participants completed metabolic testing before and after rosiglitazone including fasting determination of resistin, adiponectin, and leptin levels, serum inflammatory markers, and hyperinsulinemic euglycemic clamp testing. Resistin concentration decreased significantly after rosiglitazone (12.17 +/- 1.15 ng/ml to 10.23 +/- 1.05 ng/ml; P = 0.02), in conjunction with significant increases in adiponectin- (P < 0.001) and insulin- stimulated glucose disposal (P = 0.004). Leptin levels, as well as TNF-alpha, did not change with rosiglitazone. In summary, among HIV-infected subjects with insulin resistance and lipoatrophy, resistin levels decreased significantly after rosiglitazone. Further investigation into the physiological role of this peroxisome proliferator-activated receptor-gamma-responsive adipocytokine in the metabolic abnormalities associated with HIV is warranted.


Assuntos
Diabetes Mellitus Lipoatrófica/tratamento farmacológico , Diabetes Mellitus Lipoatrófica/etiologia , Infecções por HIV/complicações , Hormônios Ectópicos/sangue , Tiazolidinedionas/uso terapêutico , Adulto , Contagem de Linfócito CD4 , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Hipoglicemiantes/uso terapêutico , Masculino , Pessoa de Meia-Idade , PPAR gama/antagonistas & inibidores , Resistina , Rosiglitazona
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...